{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "La insuficiencia card\u00edaca cr\u00f3nica se ha convertido en uno de los mayores problemas de salud a nivel global; 23 millones de personas padecen esta patolog\u00eda en todo el mundo y su edad de aparici\u00f3n ha variado notablemente en los \u00faltimos cinco decenios, coincidiendo incluso con otras comorbilidades en la medida en que aumenta la longevidad en la poblaci\u00f3n. El tratamiento de la insuficiencia card\u00edaca tambi\u00e9n ha mostrado variaciones impresionantes durante los \u00faltimos a\u00f1os. Tal es el caso del cambio en el tratamiento de las drogas simpaticomim\u00e9ticas por los agentes betabloqueadores, que implica sobre todo un cambio conceptual en la interpretaci\u00f3n fisiopatol\u00f3gica de este s\u00edndrome. La incorporaci\u00f3n al tratamiento de la insuficiencia card\u00edaca de los f\u00e1rmacos inhibidores de la enzima convertidora de la angiotensina y de los bloqueadores de los receptores de la angiotensina ha significado un gran paso de avance en el tratamiento de pacientes con esta patolog\u00eda al disminuir significativamente su mortalidad y morbilidad. La m\u00e1s reciente introducci\u00f3n de la droga identificada como angiotensin receptor\u0096neprilysin inhibitor (LCZ696), lanzada en agosto 2014, con una aun mayor disminuci\u00f3n de la mortalidad y morbilidad de la insuficiencia card\u00edaca y menos efectos secundarios, ofrece una valedera esperanza para el tratamiento de esta patolog\u00eda. El entrenamiento y la actividad f\u00edsica es otra \u00e1rea de tratamiento que est\u00e1 siendo completamente revalorada. Se revisan aqu\u00ed aspectos fisiopatol\u00f3gicos que vinculan la pr\u00e1ctica del ejercicio f\u00edsico sistem\u00e1tico con la insuficiencia card\u00edaca y c\u00f3mo se relacionan con la evoluci\u00f3n cl\u00ednica, morbilidad y mortalidad del paciente entrenado."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27636114",
  "DateCompleted": {
    "Year": "2017",
    "Month": "07",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "10",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "09",
        "Day": "05"
      }
    ],
    "Language": [
      "spa"
    ],
    "ELocationID": [
      "10.5867/medwave.2016.6517"
    ],
    "Journal": {
      "ISSN": "0717-6384",
      "JournalIssue": {
        "Volume": "16 Suppl 4",
        "PubDate": {
          "Year": "2016",
          "Month": "Sep",
          "Day": "05"
        }
      },
      "Title": "Medwave",
      "ISOAbbreviation": "Medwave"
    },
    "ArticleTitle": "[Physical training in chronic heart failure: pathophysiology and clinical evolution].",
    "Pagination": {
      "StartPage": "e6517",
      "MedlinePgn": "e6517"
    },
    "Abstract": {
      "AbstractText": [
        "Chronic heart failure has become one of the main global health problems; 23 million people suffer from this disease worldwide and age of onset has varied considerably over the past five decades, coinciding with other co-morbidities as longevity in the population increases. Treatment of heart failure has also shown striking variations in recent years. Such is the case of the substitution of sympathomimetic drugs by beta-blocking agents, which primarily means a conceptual change in the pathophysiological interpretation of this syndrome. Incorporating to the treatment of heart failure drugs such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers has meant a great step forward in the treatment of patients with this condition that significantly has decreased mortality and morbidity. The latest introduction of the drug identified as angiotensin receptor-neprilysin inhibitor (LCZ696), launched in August 2014 with an even greater reduction in mortality and morbidity of heart failure and fewer side effects, offers a valid hope in the treatment of this pathology. Training and physical activity is another area of treatment being completely reassessed. Pathophysiological aspects that link the practice of systematic physical exercise with heart failure and how they both relate to clinical outcomes, morbidity and mortality in the trained patient are reviewed in this paper."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centro de Rehabilitaci\u00f3n del Instituto de Cardiolog\u00eda y Cirug\u00eda Cardiovascular, La Habana, Cuba. Address: Calle 17 702, Vedado, La Habana, Cuba. Email: crehab@infomed.sld.cu."
          }
        ],
        "LastName": "Rivas Estany",
        "ForeName": "Eduardo",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centro de Rehabilitaci\u00f3n del Instituto de Cardiolog\u00eda y Cirug\u00eda Cardiovascular, La Habana, Cuba."
          }
        ],
        "LastName": "Hern\u00e1ndez Garc\u00eda",
        "ForeName": "Susana",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "Entrenamiento f\u00edsico en la insuficiencia card\u00edaca cr\u00f3nica: fisiopatolog\u00eda y evoluci\u00f3n cl\u00ednica."
  },
  "MedlineJournalInfo": {
    "Country": "Chile",
    "MedlineTA": "Medwave",
    "NlmUniqueID": "101581949",
    "ISSNLinking": "0717-6384"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cardiovascular Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "adverse effects",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Cardiovascular Agents"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Exercise"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Exercise Therapy"
    },
    {
      "QualifierName": [
        "mortality",
        "physiopathology",
        "therapy"
      ],
      "DescriptorName": "Heart Failure"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    }
  ]
}